Hutchmed China Ltd - Hong Kong-based biopharmaceutical company - Receives approval for Tazverik from the Health Commission & Medical Products Administration of the Hainan province in China. The approval is for use in the Hainan pilot zone under the Clinically Urgently Needed Imported Drugs scheme, for the treatment of certain patients with epithelioid sarcoma and follicular lymphoma.
Tazverik is an oral, twice-daily treatment for cancer. Epithelioid sarcoma is a slow-growing type of soft tissue cancer and follicular lymphoma is a cancer of the lymphatic system.
Tazverik was developed by Epizyme Inc. In August, Hutchmed entered into a strategic collaboration with Epizyme to research, develop, manufacture and commercialize Tazverik in China, Hong Kong, Macau and Taiwan.
Current stock price: 169.00 pence, up 2.7% on Wednesday
12-month change: down 60%
By Abby Amoakuh; abbyamoakuh@alliancenews.com
Copyright 2022 Alliance News Limited. All Rights Reserved.
Hutchmed (HCM)